To examine whether KDM2B modulates the response of GBM cells to proapoptotic agents that trigger intrinsic apoptosis, besides the extrinsic apoptosis that is triggered by TRAIL, we conducted cell viability experiments with Bcl-2/Bcl-XL inhibitors, ABT-263 and ABT-737 (Supplementary Figures 7 and 8). Here, BCL2 is linked to glioblastoma.